Table 2.
Univariate and multivariate Cox analyses for mPFS and mOS
| mPFS | mOS | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
| HR | 95%CI | p value | HR | 95%CI | p value | HR | 95%CI | p value | HR | 95%CI | p value | |
| Age,years | ||||||||||||
| ≤ 60 vs > 60 | 1.178 | 0.181–1.712 | 0.384 | 0.930 | 0.568–1.525 | 0.930 | ||||||
| Menopausal status | ||||||||||||
| Pre- vs postmenopausal | 1.170 | 0.861–1.589 | 0.316 | 0.989 | 0.664–1.472 | 0.956 | ||||||
| IHC profile | ||||||||||||
| Triple-negative vs Luminal | 1.059 | 0.661–1.699 | 0.811 | 1.128 | 0.846–1.504 | 0.411 | ||||||
| HER2-positive vs Luminal | 1.030 | 0.735–1.443 | 0.863 | 0.980 | 0.633–1.518 | 0.929 | ||||||
| Location of metastases | ||||||||||||
| Visceral vs non-visceral | 2.728 | 1.862–3.997 | < 0.001 | 3.786 |
2.545 –5.633 |
< 0.001 | 4.066 | 2.113–7.826 | < 0.001 | 4.976 | 2.575–9.618 | < 0.001 |
| Postoperative TNM staging | ||||||||||||
| I-II vs III | 0.763 | 0.550–1.058 | 0.104 | 0.836 | 0.552–1.266 | 0.396 | ||||||
| Previous chemotherapy | ||||||||||||
| Yes vs No | 1.359 | 0.795–2.322 | 0.262 | 0.980 | 0.520–1.844 | 0.949 | ||||||
| Previous endocrine therapy | ||||||||||||
| Yes vs No | 0.973 | 0.702–1.349 | 0.871 | 0.812 | 0.536–1.230 | 0.325 | ||||||
| Previous radiotherapy | ||||||||||||
| Yes vs No | 1.264 | 0.894–1.786 | 0.185 | 1.507 | 0.944–2.405 | 0.086 | ||||||
| Plasma sPD-L1 level | ||||||||||||
| ≥ 8,774 vs <8.774 | 2.342 | 1.720–3.189 | < 0.001 | 3.358 |
2.425– 4.650 |
< 0.001 | 2.286 | 1.530–3.415 | < 0.001 | 2.792 | 1.863–4.184 | < 0.001 |
Abbreviations: sPD-L1, soluble programmed death-ligand 1; IHC, immunohistochemical; HR, hazard ratio; CI, confidence interval; mPFS, metastatic progression-free survival
Bold values indicate univariate and multivariate analyses identified high sPD-L1 level (≥ 8.774 ng/ml) and visceral metastasis were independent factors associated with poor prognosis